{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:01:07Z","timestamp":1790870467526,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Somatostatin-receptor (SSTR)-targeted PET\/CT provides important clinical information in addition to standard imaging in meningioma patients. [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE is a novel,\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled SSTR-targeting peptide with superior imaging properties according to preliminary data. We provide the first [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE PET\/CT data of a large cohort of meningioma patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with known or suspected meningioma undergoing [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE PET\/CT were included. Uptake intensity (SUV) of meningiomas, non-meningioma lesions, and healthy organs were assessed using a 50% isocontour volume of interest (VOI) or a spherical VOI, respectively. Also, trans-osseous extension on PET\/CT was assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 107 patients with 117 [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE PET\/CT scans were included. Overall, 231 meningioma lesions and 61 non-meningioma lesions (e.g., post-therapeutic changes) were analyzed. Physiological uptake was lowest in healthy brain tissue, followed by bone marrow, parotid, and pituitary (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      0.06\u2009\u00b1\u20090.04 vs. 1.4\u2009\u00b1\u20090.9 vs. 1.6\u2009\u00b1\u20091.0 vs. 9.8\u2009\u00b1\u20094.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUV\n                      <jats:sub>max<\/jats:sub>\n                      11.6\u2009\u00b1\u200910.6 vs. 4.0\u2009\u00b1\u20093.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6\u00b110.6 vs. 4.0\u00b13.3, p&lt;0.001). 93\/231 (40.3%) meningiomas showed partial trans-osseous extension and 34\/231 (14.7%) predominant intra-osseous extension. 59\/231 (25.6%) meningioma lesions found on PET\/CT had not been reported on previous standard imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This is the first PET\/CT study using an\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled SSTR-ligand in meningioma patients: [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE provides extraordinary contrast in meningioma compared to healthy tissue and non-meningioma lesions, which leads to a high detection rate of so far unknown meningioma sites and osseous involvement. Having in mind the advantageous logistic features of\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled compared to\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled compounds (e.g., longer half-life and large-badge production), [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE has the potential to foster a widespread use of SSTR-targeted imaging in neuro-oncology.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06315-z","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T07:01:48Z","timestamp":1687762908000},"page":"3390-3399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Next-generation PET\/CT imaging in meningioma\u2014first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-1198","authenticated-orcid":false,"given":"Marcus","family":"Unterrainer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Kunte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jurkschat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"W\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schirrmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg-Christian","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"6315_CR1","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23:1821\u201334.","journal-title":"Neuro Oncol"},{"key":"6315_CR2","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3389\/fonc.2020.579599","volume":"10","author":"K Huntoon","year":"2020","unstructured":"Huntoon K, Toland AMS, Dahiya S. Meningioma: a review of clinicopathological and molecular aspects. Front Oncol. 2020;10:2245.","journal-title":"Front Oncol"},{"key":"6315_CR3","doi-asserted-by":"publisher","first-page":"i44","DOI":"10.1093\/neuonc\/noy143","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Foug\u00e8re C, Schmidt NO, et al. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol. 2019;21:i44\u201361. https:\/\/doi.org\/10.1093\/neuonc\/noy143.","journal-title":"Neuro Oncol"},{"key":"6315_CR4","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/neuonc\/noy181","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F, Tabatabai G, Aldape K, Zadeh G. Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas. Neuro Oncol. 2019;21:i2\u20133. https:\/\/doi.org\/10.1093\/neuonc\/noy181.","journal-title":"Neuro Oncol"},{"key":"6315_CR5","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","volume":"19","author":"N Galldiks","year":"2017","unstructured":"Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma\u2014report of the RANO\/PET Group. Neuro Oncol. 2017;19:1576\u201387.","journal-title":"Neuro Oncol"},{"key":"6315_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/cancers13092093","volume":"13","author":"A Holzgreve","year":"2021","unstructured":"Holzgreve A, Albert NL, Galldiks N, Suchorska B. Use of PET imaging in neuro-oncological surgery. Cancers. 2021;13:2093.","journal-title":"Cancers"},{"key":"6315_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105:212\u201344.","journal-title":"Neuroendocrinology"},{"key":"6315_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/ph14070701","volume":"14","author":"L Gower-Fry","year":"2021","unstructured":"Gower-Fry L, Kronemann T, Dorian A, Pu Y, Jaworski C, W\u00e4ngler C, et al. Recent Advances in the clinical translation of silicon fluoride acceptor (SiFA) 18F-radiopharmaceuticals. Pharmaceuticals. 2021;14:701.","journal-title":"Pharmaceuticals"},{"key":"6315_CR9","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/s41596-020-00407-y","volume":"15","author":"S Lindner","year":"2020","unstructured":"Lindner S, W\u00e4ngler C, Bailey JJ, Jurkschat K, Bartenstein P, W\u00e4ngler B, et al. Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc. 2020;15:3827\u201343. https:\/\/doi.org\/10.1038\/s41596-020-00407-y.","journal-title":"Nat Protoc"},{"key":"6315_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, W\u00e4ngler C, W\u00e4ngler B, et al. Automated production of [18F]SiTATE on a Scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88\u201389:86\u201395. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.07.008.","journal-title":"Nucl Med Biol"},{"key":"6315_CR11","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","volume":"48","author":"L Beyer","year":"2021","unstructured":"Beyer L, Gosewisch A, Lindner S, V\u00f6lter F, Mittlmeier LM, Tiling R, et al. Dosimetry and optimal scan time of [18F]SiTATE-PET\/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021;48:3571\u201381. https:\/\/doi.org\/10.1007\/s00259-021-05351-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:870\u201380. https:\/\/doi.org\/10.1007\/s00259-019-04501-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR13","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1007\/s00259-019-04448-8","volume":"46","author":"H Ilhan","year":"2019","unstructured":"Ilhan H, Todica A, Lindner S, Boening G, Gosewisch A, W\u00e4ngler C, et al. First-in-human 18 F-SiFAlin-TATE PET\/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46:2400\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1021\/bc100316c","volume":"21","author":"C W\u00e4ngler","year":"2010","unstructured":"W\u00e4ngler C, Waser B, Alke A, Iovkova L, Buchholz H-G, Niedermoser S, et al. One-step 18F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem. 2010;21:2289\u201396.","journal-title":"Bioconjug Chem"},{"key":"6315_CR15","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1002\/anie.200600795","volume":"45","author":"R Schirrmacher","year":"2006","unstructured":"Schirrmacher R, Bradtm\u00f6ller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, et al. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed. 2006;45:6047\u201350.","journal-title":"Angew Chem Int Ed"},{"key":"6315_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5603\/NMR.2014.0022","volume":"17","author":"A d'Amico","year":"2014","unstructured":"d\u2019Amico A, Gorczewska I, Gorczewski K, Turska-d\u2019Amico M, Di Pietro M. Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography\/computed tomography on urine radioactivity and detection of uterine cervical cancer. Nucl Med Rev. 2014;17:83\u20136.","journal-title":"Nucl Med Rev"},{"key":"6315_CR17","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","volume":"58","author":"WG Kunz","year":"2017","unstructured":"Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58:1580\u20137.","journal-title":"J Nucl Med"},{"key":"6315_CR18","doi-asserted-by":"crossref","unstructured":"Hartmann H, Z\u00f6phel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET\/CT examinations. Nuklearmedizin-NuclearMedicine. 2009;48:201\u20137.","DOI":"10.3413\/nukmed-0214"},{"key":"6315_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409\u201315. https:\/\/doi.org\/10.1007\/s00259-012-2155-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR20","doi-asserted-by":"publisher","unstructured":"Al-Rashed M, Foshay K, Abedalthagafi M. Recent advances in meningioma immunogenetics. Frontiers in Oncology. 2020;9:1472. https:\/\/doi.org\/10.3389\/fonc.2019.01472.","DOI":"10.3389\/fonc.2019.01472"},{"key":"6315_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","volume":"21","author":"A Ben-Shlomo","year":"2010","unstructured":"Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123\u201333.","journal-title":"Trends Endocrinol Metab"},{"key":"6315_CR22","doi-asserted-by":"publisher","first-page":"e2512","DOI":"10.1212\/WNL.0000000000007544","volume":"92","author":"M Unterrainer","year":"2019","unstructured":"Unterrainer M, Ruf V, Ilhan H, Vettermann F, Holzgreve A, Cyran CC, et al. Teaching neuroImages: advanced imaging of neurosarcoidosis with 68Ga-DOTATATE PET\/CT. Neurology. 2019;92:e2512\u20133.","journal-title":"Neurology"},{"key":"6315_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/RLU.0000000000001793","volume":"42","author":"M Unterrainer","year":"2017","unstructured":"Unterrainer M, Ilhan H, Todica A, Bartenstein P, Albert NL. Epidural metastases from follicular thyroid cancer mimicking meningiomas in 68Ga-DOTATATE PET. Clin Nucl Med. 2017;42:805\u20136.","journal-title":"Clin Nucl Med"},{"key":"6315_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/RLU.0000000000001985","volume":"43","author":"M Unterrainer","year":"2018","unstructured":"Unterrainer M, Maihoefer C, Cyran CC, Bartenstein P, Niyazi M, Albert NL. 68Ga-DOTATATE PET\/CT reveals Epstein-Barr virus-associated nasopharyngeal carcinoma in a case of suspected sphenoid wing meningioma. Clin Nucl Med. 2018;43:287\u20138.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"6315_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/RLU.0000000000003770","volume":"46","author":"MP Fabritius","year":"2021","unstructured":"Fabritius MP, Geyer T, Ahmaddy F, Albert NL, Bartenstein P, Tiling R, et al. Breast cancer metastasis mimicking meningioma in 68Ga-DOTATOC PET\/CT. Clin Nucl Med. 2021;46(11):922\u20133.","journal-title":"Clin Nucl Med."},{"key":"6315_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/RLU.0000000000002513","volume":"44","author":"M Unterrainer","year":"2019","unstructured":"Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, et al. 68Ga-DOTATOC PET\/CT differentiates meningioma from dural metastases. Clin Nucl Med. 2019;44:412\u20133.","journal-title":"Clin Nucl Med"},{"key":"6315_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3171\/2009.2.JNS08877","volume":"111","author":"D Gabeau-Lacet","year":"2009","unstructured":"Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009;111:464\u201371.","journal-title":"J Neurosurg"},{"key":"6315_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-019-1341-x","volume":"14","author":"K Zwirner","year":"2019","unstructured":"Zwirner K, Paulsen F, Schittenhelm J, Gepfner-Tuma I, Tabatabai G, Behling F, et al. Integrative assessment of brain and bone invasion in meningioma patients. Radiat Oncol. 2019;14:1\u20139.","journal-title":"Radiat Oncol"},{"key":"6315_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3171\/JNS-07\/11\/0905","volume":"107","author":"K Bikmaz","year":"2007","unstructured":"Bikmaz K, Mrak R, Al-Mefty O. Management of bone-invasive, hyperostotic sphenoid wing meningiomas. J Neurosurg. 2007;107:905\u201312.","journal-title":"J Neurosurg"},{"key":"6315_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10143-021-01642-x","volume":"45","author":"J Haslund-Vinding","year":"2022","unstructured":"Haslund-Vinding J, M\u00f8ller JR, Ziebell M, Vilhardt F, Mathiesen T. The role of systemic inflammatory cells in meningiomas. Neurosurg Rev. 2022;45:1205\u201315. https:\/\/doi.org\/10.1007\/s10143-021-01642-x.","journal-title":"Neurosurg Rev"},{"key":"6315_CR31","doi-asserted-by":"crossref","unstructured":"Proctor DT, Huang J, Lama S, Albakr A, Van Marle G, Sutherland GR. Tumor-associated macrophage infiltration in meningioma. Neuro-Oncol Adv. 2019;1:vdz018.","DOI":"10.1093\/noajnl\/vdz018"},{"key":"6315_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.112.114165","volume":"54","author":"RC Walker","year":"2013","unstructured":"Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855\u201360.","journal-title":"J Nucl Med"},{"key":"6315_CR33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Velikyan I, Garske-Rom\u00e1n U, S\u00f6rensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755\u20139.","journal-title":"J Nucl Med"},{"key":"6315_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00259-018-4193-y","volume":"46","author":"S Krebs","year":"2019","unstructured":"Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, et al. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:677\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00259-018-3939-x","volume":"45","author":"D Plyku","year":"2018","unstructured":"Plyku D, Mena E, Rowe SP, Lodge MA, Szabo Z, Cho SY, et al. Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. Eur J Nucl Med Mol Imaging. 2018;45:989\u201398.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR36","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.118.225250","volume":"60","author":"S Piron","year":"2019","unstructured":"Piron S, De Man K, Van Laeken N, D\u2019Asseler Y, Bacher K, Kersemans K, et al. Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer. J Nucl Med. 2019;60:1736\u201342.","journal-title":"J Nucl Med"},{"key":"6315_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0540-7","volume":"9","author":"M Hohberg","year":"2019","unstructured":"Hohberg M, Kobe C, Krapf P, T\u00e4ger P, Hammes J, Dietlein F, et al. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET\/CT imaging of prostate cancer. EJNMMI Res. 2019;9:1\u201310.","journal-title":"EJNMMI Res"},{"key":"6315_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2967\/jnumed.117.199554","volume":"59","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, et al. Cold kit for prostate-specific membrane antigen (PSMA) PET imaging: phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET\/CT in patients with prostate cancer. J Nucl Med. 2018;59:625\u201331.","journal-title":"J Nucl Med"},{"key":"6315_CR39","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","volume":"46","author":"E Pauwels","year":"2019","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging. 2019;46:2398\u20139. https:\/\/doi.org\/10.1007\/s00259-019-04425-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","volume":"44","author":"T Long","year":"2019","unstructured":"Long T, Yang N, Zhou M, Chen D, Li Y, Li J, et al. Clinical application of 18F-AlF-NOTA-octreotide PET\/CT in combination with 18F-FDG PET\/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44:452\u20138.","journal-title":"Clin Nucl Med"},{"key":"6315_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, et al. Automated GMP compliant production of [18F] AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5:1\u201323.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"6315_CR42","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04918-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6315_CR43","doi-asserted-by":"crossref","unstructured":"Goffin K. Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two \u2018new kids on the block\u2019in somatostatin receptor imaging. Springer; 2019. p. 2225\u20137.","DOI":"10.1007\/s00259-019-04474-6"},{"key":"6315_CR44","doi-asserted-by":"crossref","unstructured":"Sahnoun S, Conen P, Mottaghy FM. The battle on time, money and precision: Da [18F] id vs.[68Ga] liath. Springer; 2020. p. 2944\u20136.","DOI":"10.1007\/s00259-020-04961-1"},{"issue":"4","key":"6315_CR45","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2022","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2022;64(4):632\u20138.","journal-title":"J Nucl Med."},{"key":"6315_CR46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, P\u00f6schl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347\u201353.","journal-title":"J Nucl Med"}],"updated-by":[{"DOI":"10.1007\/s00259-023-06409-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06315-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06315-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06315-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T02:02:41Z","timestamp":1696039361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06315-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6315"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06315-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-023-06409-8","URL":"https:\/\/doi.org\/10.1007\/s00259-023-06409-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JCT received research grants from Novocure and Munich Surgical Imaging and lecture honoraria from Seagen. NLA received research grants from Novocure and honoraria for consultation or advisory board participation from Novartis and Telix. All other authors do not declare any potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}